The Firm is representing EQT VIII Fund in its announced definitive agreement to acquire a majority interest in Aldevron. Founders, management and TA Associates will retain a minority stake.
Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is the leading global supplier of GMP, GMP-SourceTM and Research Grade plasmid DNA used in commercial, clinical and research stage gene therapies, as well as proteins, antibodies and mRNA. Aldevron’s custom development and manufacturing capabilities enable scientists worldwide to develop groundbreaking new therapies with a focus on quality, speed and innovation. Aldevron is based in Fargo, North Dakota and has additional operations in Madison, Wisconsin and Freiburg, Germany.
EQT is a leading investment firm with more than EUR 61 billion in raised capital across 29 funds and around EUR 40 billion in assets under management. EQT funds have portfolio companies in Europe, Asia and the U.S. with total sales of more than EUR 21 billion and approximately 127,000 employees.
The Simpson Thacher team includes Patrick Naughton, Naveed Anwar, Simon Chiu, Mark Underwood, Michael Schaeppi, Laura Berzins, Brittani Frink, Estell Lee and Megan Whitman (M&A); Jennifer Hobbs, Eli Isak and Oliver Sall (Credit); Jonathan Goldstein and Jacqueline Clinton (Tax); Jason Glover and Robert Lee (Private Funds); David Rubinsky, Patricia Adams and Jake Phillips (Employee Benefits and Executive Compensation); Sara Razi, Kelly Karapetyan and Tomi Mendel (Antitrust); Timothy Mulvihill and Adeeb Fadil (Environmental); Lori Lesser and Alysha Sekhon (Intellectual Property); and Krista McManus (Real Estate). Summer Associates Marina Hernandez and Tom Hao provided valuable assistance.